Aficamten: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|April 6, 2026
Summary
Aficamten is a new cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy (HCM). This medication improves function and symptoms in adults with obstructive HCM, marking a significant advancement in cardiovascular treatment.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease.
- Obstructive HCM (oHCM) significantly impacts patient quality of life.
- Limited treatment options exist for symptomatic oHCM.
Purpose of the Study:
- To summarize the development milestones of aficamten.
- To highlight the regulatory approvals for aficamten in oHCM.
- To review the clinical trial data supporting aficamten's efficacy.
Main Methods:
- Phase III, randomized, double-blind, placebo-controlled SEQUOIA-HCM trial.
- Evaluation of aficamten's effect on functional capacity and symptoms.
- Assessment of safety and tolerability profiles.
Main Results:
- Aficamten demonstrated significant improvements in functional capacity and symptoms in adults with oHCM.
- Regulatory approvals obtained in China, USA, and EU based on trial findings.
- Ongoing Phase III evaluation for non-obstructive HCM (nHCM).
Conclusions:
- Aficamten represents a novel therapeutic option for symptomatic obstructive HCM.
- The drug's development highlights successful progression from clinical trials to market approval.
- Further research is underway to expand its therapeutic applications.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
330
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
330
01:26Drug Administration and Therapy Phases: Overview
1.7K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.7K
01:25Drug Regulation
3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
01:02Prescription, Nonprescription and Orphan Drugs
1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
01:19Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K